Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged over the past decade as a
post-transcriptional regulator of the LDL receptor (LDL-R). PCSK9 acts as an endogenous
natural inhibitor of the LDL-R pathway. Monoclonal antibodies (mAb) directed against PCSK9,
such as Alirocumab, are the most common method of PCSK9 inhibition.
The goal of the present study is to assess, in the context of type 2 diabetes, a situation
associated with an increased post-prandial hyperlipemia, whether PCSK9 inhibition with
Alirocumab affects postprandial intestinal lipoprotein metabolism.